Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avid Corp., Triangle deal

VIRS will acquire Avid, a privately held developer of antiviral therapies, for $1.25 million in cash

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE